Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging
Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of its prostate cancer imaging product.
Telix is pleased to announce its subsidiary, Telix Pharmaceuticals Japan KK has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography (PET).
The Phase I trial, which will enroll 10 patients with advanced prostate cancer, will be the first clinical trial involving the use of gallium-based PSMA imaging in Japan. Telix has developed TLX591-CDx as a next-generation PET imaging agent that targets prostate-specific membrane antigen (PSMA), which is expressed on the surface of prostate cancer cells. PSMA imaging has emerged as a new standard of care in prostate cancer imaging globally and is already included in clinical practice guidelines in the United States and Europe.
Dr. Shintaro Nishimura, President of Telix Japan, stated “It is a great pleasure to work with Kanazawa University, which is the oldest Department of Nuclear Medicine in Japan. Through this collaboration, we take a first critical step toward providing PSMA imaging to Japanese men with prostate cancer. The annual incidence of prostate cancer in Japan is 70,000 patients with this figure expected to rise over coming years. As such, there is an urgent need to deliver this break-through imaging modality to Japanese patients without delay. We wish to thank Kanazawa University’s Departments of Nuclear Medicine and Urology, the Innovative Clinical Research Center (iCREK), and the Kanazawa Advanced Medical Center (KadMedic) for their support in bringing this important clinical study to realisation.”
Prof. Seigo Kinuya, Professor of Nuclear Medicine at the Kanazawa University Hospital, Department of Nuclear Medicine, Chair of the Japanese Society of Nuclear Medicine, and Chair of the National Conference for Nuclear Medicine Theranostics, added, “The Third-Term Comprehensive 10-year Strategy for Cancer Control, a nationwide initiative advocating the promotion of radiation therapy, has been in place since 2004. In order to deliver on this initiative, concrete development of new diagnostic and therapeutic agents in Japan is essential. Our collaboration with Telix Japan and this first clinical trial of 68Ga-PSMA-11 prostate imaging in Japan are important milestones in the progress of Japanese nuclear medicine. We look forward to providing new diagnostics to patients in Japan as early as possible in collaboration with Telix.”
To read the full media release please click here.
Telix Seneffe Production Facility: Progress Update
Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical...
Activities Report and Appendix 4C for June 2021 Quarter
Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Melbourne (Australia) – 20 July 2021. Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer...
Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA
19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa...
Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations
Melbourne (Australia) – 12 July 2021. Telix announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in...
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Melbourne (Australia) – 23 June 2021. Telix announces that a first patient has been dosed in a Phase I study...
IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update
Melbourne (Australia) – 21 June 2021. Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on...
Telix Update on FDA New Drug Application Review for Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....
Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...
Telix launches “Gallium Wave” Awareness Website
Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...
Scott Law joins Telix as SVP Global Manufacturing Operations
11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...